In 2025, the United States launched a bold new wave of tariffs, targeting imports critical to the pharmaceutical and healthcare industries. These policies, driven by a push to strengthen domestic manufacturing, impose a 10% tariff on all imported goods, alongside steeper levies of up to 245% on Chinese active pharmaceutical ingredients (APIs) and 25% on medical devices from Canada and Mexico. While aimed at boosting local production, these 2025 U.S. tariffs have created significant challenges for drugmakers and healthcare providers. The increased costs of APIs, medical devices, and other essentials are straining supply chains, driving up drug and device prices, and ri...
